Enliven Therapeutics, Inc.
ELVN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,045,227 | $985,004 | $1,121,805 |
| - Cash | $101,732 | $119,437 | $101,705 | $124,117 |
| + Debt | $0 | $376 | $365 | $0 |
| Enterprise Value | – | $926,166 | $883,664 | $997,688 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$20,086 | -$28,503 | -$31,619 | -$26,816 |
| % Margin | – | – | – | – |
| Net Income | -$20,148 | -$25,335 | -$28,544 | -$23,180 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.32 | -0.49 | -0.57 | -0.46 |
| % Growth | 34.7% | 14% | -23.9% | – |
| Operating Cash Flow | -$13,279 | -$17,057 | -$24,127 | -$17,203 |
| Capital Expenditures | $1 | -$139 | -$20 | $0 |
| Free Cash Flow | -$13,278 | -$17,196 | -$24,147 | -$17,203 |